Universal Health Services, Inc. (UHS) Q3 2024 Earnings Call Transcript Summary
Universal Health Services, Inc. (UHS) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Universal Health Services, Inc. (UHS) Q3 2024 Earnings Call Transcript:
以下是Universal Health Services, Inc.（UHS）2024年第三季度業績會議呼叫記錄摘要：
Financial Performance:
金融業績：
UHS reported adjusted net income per diluted share of $3.71 for Q3 2024.
Revenue growth for the quarter was solid at 8.6%, excluding impacts from the insurance subsidiary.
EBITDA at acute care hospitals increased substantially by 36% compared to the prior year quarter on the same facility basis.
UHS報告2024年第三季度調整後每股稀釋淨利潤爲3.71美元。
本季度營業收入增長穩健，達到8.6%，不包括保險子公司的影響。
急性護理醫院的EBITDA按同一設施基礎上較上一年同期大幅增長36%。
Business Progress:
業務進展：
Acute care volumes have moderated but are returning to pre-pandemic patterns.
Opened the 128 bed Riva Vista Behavioral Health Hospital and progressing with construction of other facilities.
Continuous development in both acute and behavioral health segments, including joint ventures and capacity expansions.
急性護理病例數量有所穩定，但正在恢復至疫情前的模式。
開設了擁有128張牀位的Riva Vista心理健康醫院，並正在推進其他醫療設施的施工。
在急性和行爲健康領域不斷髮展，包括合資經營和擴 capacity。
Opportunities:
機會：
Medicaid supplemental payment programs, especially new approvals in Tennessee and Washington, D.C., could lead to substantial financial benefits.
Expansion and development in both inpatient and ambulatory care facilities.
醫療補充付款計劃，特別是在田納西州和華盛頓特區的新批准，可能帶來可觀的財務利益。
在住院和門診護理設施的擴建和發展。
Risks:
風險：
Increase in reserves for self-insured claims indicates potential issues in liability management.
Aggressive behavior from managed care payers, with no significant change noted in the current quarter.
爲自保索賠提高儲備表明責任管理可能存在潛在問題。
託管付款機構的激進行爲，當前季度未見顯著變化。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。
